Table 1.
Baseline characteristics of the study participants (n = 56)
| Baseline characteristics | MCI converters | MCI non-converters |
|---|---|---|
| Gender, %, female | 60.52 | 38.89 |
| APOE ε4 status, % | 50 | 44.44 |
| Age at baseline, mean ± SD | 76.02 ± 7.81 | 78.06 ± 5.08 |
| MMSE at baseline, mean ± SD | 26.78 ± 1.97 | 27.94 ± 1.43 |
| Education in years, mean ± SD | 8.95 ± 4.53 | 12.83 ± 3.09 |
| Years from baseline until conversion or last assessment [range] | 1.30 ± 0.69 [1–3.42] | 3.36 ± 1.66 [0.92–5.83] |
| Comorbidities (objective and self-reported) | ||
| ȃHypertension | 12 (31.58%) | 10 (55.56%) |
| ȃHeart attack ever | 1 (2.63%) | 4 (22.22%) |
| ȃAngina | 5 (13.16%) | 4 (22.22%) |
| ȃDepression | 19 (50%) | 9 (50%) |
| ȃArthritis | 1 (2.63%) | 3 (16.67%) |
| ȃAsthma | 2 (5.26%) | 1 (5.56%) |
| ȃCancer | 5 (13.16%) | 8 (44.44%) |
| ȃGlaucoma | 2 (5.26%) | 1 (5.55%) |
| ȃHypothyroidism | 6 (15.79%) | 8 (44.44%) |
| ȃInfections, allergies | 5 (13.16%) | 2 (11.11%) |
| ȃStroke/transient ischaemic attack | 2 (5.26%) | 2 (11.11%) |
| ȃDiabetes | 7 (18.42%) | 2 (11.11%) |
| Drug intake | ||
| ȃAntidepressants | 12 (31.58%) | 3 (16.67%) |
| ȃNSAIDs (with aspirins for platelet control) | 11 (28.95%) | 8 (44.44%) |
| ȃAnalgesics | 5 (13.16%) | 5 (27.78%) |
| ȃAlzheimer’s disease drugs | 11 (28.95%) | 0 (0%) |
| ȃMetformin | 4 (10.53%) | 1 (5.55%) |
| ȃSleeping pills | 3 (7.89%) | 2 (11.11%) |
| ȃStatins | 13 (34.21%) | 8 (44.44%) |
| Lifestyle factors | ||
| ȃExcessive alcohol intake | 1 (2.63%) | 3 (16.67%) |
| ȃSmoking (ever) | 9 (23.68%) | 5 (27.78%) |
| ȃSolitary living | 16 (42.10%) | 9 (50%) |
| ȃSupplement intakea | 7 (18.42%) | 5 (27.78%) |
Comorbidities represent either history of disease or being presently affected. Drug intake means either having a history of medications or current intake.
Vitamins (including folic acid) and omega-3 fatty acids.